Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions

被引:248
作者
Mellins, Elizabeth D. [1 ]
Macaubas, Claudia [1 ]
Grom, Alexei A. [2 ,3 ]
机构
[1] Stanford Univ, Dept Pediat, Stanford, CA 94305 USA
[2] Cincinnati Childrens Hosp Med Ctr, Div Pediat Rheumatol, Cincinnati, OH 45229 USA
[3] Univ Cincinnati, Coll Med, Cincinnati, OH 45229 USA
关键词
MACROPHAGE-ACTIVATION SYNDROME; KILLER-CELL DYSFUNCTION; RECEPTOR ANTAGONIST ANAKINRA; MIGRATION INHIBITORY FACTOR; GENE-EXPRESSION PROFILES; RHEUMATOID-ARTHRITIS; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; DIAGNOSTIC-SIGNIFICANCE; 5'-FLANKING REGION; SCAVENGER RECEPTOR;
D O I
10.1038/nrrheum.2011.68
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Systemic juvenile idiopathic arthritis (sJIA) has long been recognized as unique among childhood arthritides, because of its distinctive clinical and epidemiological features, including an association with macrophage activation syndrome. Here, we summarize research into sJIA pathogenesis. The triggers of disease are unknown, although infections are suspects. Once initiated, sJIA seems to be driven by innate proinflammatory cytokines. Endogenous Toll-like receptor ligands, including S100 proteins, probably synergize with cytokines to perpetuate inflammation. These and other findings support the hypothesis that sJIA is an autoinflammatory condition. Indeed, IL-1 is implicated as a pivotal cytokine, but the source of excess IL-1 activity remains obscure and the role of IL-1 in chronic arthritis is less clear. Another hypothesis is that a form of hemophagocytic lymphohistiocytosis underlies sJIA, with varying degrees of its expression across the spectrum of disease. Alternatively, sJIA with MAS might be a genetically distinct subtype. Yet another hypothesis proposes that inadequate downregulation of immune activation is central to sJIA, supporting evidence for which includes 'alternative activation' of monocyte and macrophages and possible deficiencies in IL-10 and T regulatory cells. Some altered immune phenotypes persist during clinically inactive disease, which suggests that this stage might represent compensated inflammation. Despite much progress being made, many questions remain, providing fertile ground for future research.
引用
收藏
页码:416 / 426
页数:11
相关论文
共 119 条
  • [111] Verbsky JW, 2004, J RHEUMATOL, V31, P2071
  • [112] Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome
    Villanueva, J
    Lee, S
    Giannini, EH
    Graham, TB
    Passo, MH
    Filipovich, A
    Grom, AA
    [J]. ARTHRITIS RESEARCH & THERAPY, 2005, 7 (01) : R30 - R37
  • [113] Perforin-mediated target-cell death and immune homeostasis
    Voskoboinik, Ilia
    Smyth, Mark J.
    Trapani, Joseph A.
    [J]. NATURE REVIEWS IMMUNOLOGY, 2006, 6 (12) : 940 - 952
  • [114] Follistatin-like Protein 1 Is a Mesenchyme-Derived Inflammatory Protein and May Represent a Biomarker for Systemic-Onset Juvenile Rheumatoid Arthritis
    Wilson, David C.
    Marinov, Anthony D.
    Blair, Harry C.
    Bushnell, Daniel S.
    Thompson, Susan D.
    Chaly, Yury
    Hirsch, Raphael
    [J]. ARTHRITIS AND RHEUMATISM, 2010, 62 (08): : 2510 - 2516
  • [115] S100A12 Is a Novel Molecular Marker Differentiating Systemic-Onset Juvenile Idiopathic Arthritis From Other Causes of Fever of Unknown Origin
    Wittkowski, Helmut
    Frosch, Michael
    Wulffraat, Nico
    Goldbach-Mansky, Raphaela
    Kallinich, Tilmann
    Kuemmerle-Deschner, Jasmin
    Fruehwald, Michael C.
    Dassmann, Sandra
    Pham, Tuyet-Hang
    Roth, Johannes
    Foell, Dirk
    [J]. ARTHRITIS AND RHEUMATISM, 2008, 58 (12): : 3924 - 3931
  • [116] Reduced perforin expression in systemic juvenile idiopathic arthritis is restored by autologous stem-cell transplantation
    Wulffraat, NM
    Rijkers, GT
    Elst, E
    Brooimans, R
    Kuis, W
    [J]. RHEUMATOLOGY, 2003, 42 (02) : 375 - 379
  • [117] Association of IRF5 Polymorphisms with Susceptibility to Macropilage Activation Syndrome in Patients with Juvenile Idiopathic Arthritis
    Yanagimachi, Masakatsu
    Naruto, Takuya
    Miyamae, Takako
    Hara, Takuma
    Kikuchi, Masako
    Hara, Ryoki
    Imagawa, Tomoyuki
    Mori, Masaaki
    Sato, Hidenori
    Goto, Hiroaki
    Yokota, Shumpei
    [J]. JOURNAL OF RHEUMATOLOGY, 2011, 38 (04) : 769 - 774
  • [118] Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial
    Yokota, Shumpei
    Imagawa, Tomoyuki
    Mori, Masaaki
    Miyamae, Takoko
    Aihara, Yukoh
    Takei, Shuji
    Iwata, Naomi
    Umebayashi, Hiroaki
    Murata, Takuji
    Miyoshi, Mari
    Tomiita, Minako
    Nishimoto, Norihiro
    Kishimoto, Tadamitsu
    [J]. LANCET, 2008, 371 (9617) : 998 - 1006
  • [119] Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms
    Zhang, Kejian
    Biroschak, Jennifer
    Glass, David N.
    Thompson, Susan D.
    Finkel, Terri
    Passo, Murray H.
    Binstadt, Bryce A.
    Filipovich, Alexandra
    Grom, Alexei A.
    [J]. ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : 2892 - 2896